The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 09, 2025
Filed:
Jun. 20, 2023
Applicant:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Inventors:
William Querbes, Boston, MA (US);
Kevin Fitzgerald, Brookline, MA (US);
James Butler, Lynnfield, MA (US);
Stephanie Williams, Littleton, MA (US);
Gregory Hinkle, Plymouth, MA (US);
Martin A. Maier, Belmont, MA (US);
Assignee:
Alnylam Pharmaceuticals, Inc., Cambridge, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 47/54 (2017.01);
U.S. Cl.
CPC ...
C12N 15/1136 (2013.01); A61K 31/713 (2013.01); A61K 47/549 (2017.08); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/34 (2013.01); C12N 2310/344 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/32 (2013.01); C12N 2320/35 (2013.01); C12N 2320/51 (2013.01);
Abstract
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.